Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus

Cardiovascular Revascularization Medicine

Volumn 16, Issue 8, 2015, Pages 450-454

  Clavijo, Leonardo C ^a   Maya, Juan ^b   Carlson, Glenn ^b   Angiolillo, Dominick J ^c   Teng, Renli ^b   Caplan, Richard ^b   Price, Matthew J ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d SCRIPPS CLINIC   (United States)

Author keywords

Clopidogrel; Diabetes mellitus; Hispanic; Ticagrelor

Indexed keywords

CLOPIDOGREL; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ABDOMINAL PAIN; ADULT; AGED; ANTICOAGULATION; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; FEMALE; HEADACHE; HISPANIC; HUMAN; LOADING DRUG DOSE; MALE; MUSCULOSKELETAL CHEST PAIN; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIB FRACTURE; ANALOGS AND DERIVATIVES; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; COMPLICATION; CORONARY ANGIOGRAPHY; DOSE RESPONSE; DRUG ADMINISTRATION; ETHNOLOGY; FOLLOW UP; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROCEDURES; RADIOGRAPHY; REGRESSION ANALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES;

ADENOSINE; ADMINISTRATION, ORAL; AGED; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; REGRESSION ANALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TICLOPIDINE; TREATMENT OUTCOME; UNITED STATES;

EID: 84952861687     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2015.08.007     Document Type: Article

References (31)

1. Boyle J.P., Thompson T.J., Gregg E.W., Barker L.E., Williamson D.F. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modelling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 2010, 8:29.
2. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Blaha M.J., et al. Heart disease and stroke statistics - 2014 update: A report from the American Heart Association. Circulation 2014, 129:e28-e292.
3. Centers for Disease Control and Prevention National Diabetes Fact Sheet: national estimates and general information on diabetes and prediabetes in the United States 2011, US Department of Health and Human Services, Centers for Disease Control, Atlanta, GA, [Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf Last accessed 27 November 2014].
4. Kanjilal S., Gregg E.W., Cheng Y.J., Zhang P., Nelson D.E., Mensah G., et al. Socioeconomic status and trends in disparities in 4 major risk factors for cardiovascular disease among US adults, 1971-2002. Arch Intern Med 2006, 166:2348-2355.
5. Angiolillo D., Fernandez-Ortiz A., Bernardo E., Ramírez C., Sabaté M., Jimenez-Quevedo P., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005, 54:2430-2435.
6. Mylotte D., Kavanagh G.F., Peace A.J., Tedesco A.F., Carmody D., O'Reilly M., et al. Platelet reactivity in type 2 diabetes mellitus: a comparative analysis with survivors of myocardial infarction and the role of glycaemic control. Platelets 2012, 23:439-446.
7. Simpson S.H., Abdelmoneim A.S., Omran D., Featherstone T.R. Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin. Am J Med 2014, 127:95.e1-9.
8. Huxley R., Barzi F., Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006, 332:73-78.
9. El Ghannudi S., Ohlmann P., Jesel L., Radulescu B., El Adraa E., Crimizade U., et al. Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention. Atherosclerosis 2011, 217:465-472.
10. Husted S., Emanuelsson H., Heptinstall S., Sandset P.M., Wickens M., Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006, 27:1038-1047.
11. van Giezen J.J., Nilsson L., Berntsson P., Wissing B.M., Giordanetto F., Tomlinson W., et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and PA. J Thromb Haemost 2009, 7:1556-1565.
12. Husted S.E., Storey R.F., Bliden K., Tantry U.S., Høimark L., Butler K., et al. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. Clin Pharmacokinet 2012, 51:397-409.
13. Armstrong D., Summers C., Ewart L., Nylander S., Sidaway J.E., van Giezen J.J. Characterisation of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter-1. J Cardiovasc Pharmacol 2014, 19:209-219.
14. Brilinta prescribing information, revised 29 March 2013 Available at:, [Last accessed November 26, 2014]. http://www1.astrazeneca-us.com/pi/brilinta.pdf.
15. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
16. James S., Angiolillo D.J., Cornel J.H., Erlinge D., Husted S., Kontny F., et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010, 31:3006-3016.
17. Price M.J., Clavijo L., Angiolillo D.J., Carlson G., Caplan R., Teng R., et al. A randomized trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease. J Thromb Thrombolysis 2015, 39:8-14.
18. Malinin A., Pokov A., Swaim L., Kotob M., Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 2006, 28:315-322.
19. Malinin A., Pokov A., Spergling M., Defranco A., Schwartz K., Schwartz D., et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: the VERIfy Thrombosis risk Assessment (VERITAS) study. Thromb Res 2007, 119:277-284.
20. Tantry U.S., Bonello L., Aradi D., Price M.J., Jeong Y.H., Angiolillo D.J., et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013, 62:2261-2273.
21. US Census Bureau USA people quick facts Available from:, [Last accessed November 26, 2014]. http://quickfacts.census.gov/qfd/states/00000.html.
22. Daviglus M.L., Talavera G.A., Avilés-Santa M.L., Allison M., Cai J., Criqui M.H., et al. Prevalence of major cardiovascular risk factors and cardiovascular diseases among Hispanic/Latino individuals of diverse backgrounds in the United States. JAMA 2012, 308:1775-1784.
23. Waksman R., Maya J., Angiolillo D., Carlson G., Teng R., Caplan R., et al. Ticagrelor versus clopidogrel in black patients with stable coronary artery disease: a randomized, open-label, multiple-dose, crossover study. Circ Cardiovasc Interv 2015, 8.
24. Gurbel P.A., Bliden K.P., Butler K., Tantry U.S., Gesheff T., Wei C., et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009, 120:2577-2585.
25. Wiviott S.D., Braunwald E., Angiolillo D.J., Meisel S., Dalby A.J., Verheugt F.W., et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes By Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008, 118:1626-1636.
26. Morel O., El Ghannudi S., Hess S., Reydel A., Crimizade U., Jesel L., et al. The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight. Thromb Haemost 2012, 108:338-348.
27. Kuliczkowski W., Gasior M., Pres D., Kaczmarski J., Greif M., Łaszewska A., et al. Effect of glycemic control on response to antiplatelet therapy in patients with diabetes mellitus and ST-segment elevation myocardial infarction. Am J Cardiol 2012, 110:331-336.
28. Price M.J. Diabetes mellitus and clopidogrel response variability. J Am Coll Cardiol 2014, 64:1015-1018.
29. Erlinge D., Varenhorst C., Braun O.O., James S., Winters K.J., Jakubowski J.A., et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulation active metabolite, but their platelets respond normally active metabolite added ex vivo. J Am Coll Cardiol 2008, 52:1968-1977.
30. Angiolillo D.J., Jakubowski J.A., Ferreiro J.L., Tello-Montoliu A., Rollini F., Franchi F., et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol 2014, 64:1005-1014.
31. Angiolillo D.J., Bernardo E., Capodanno D., Vivas D., Sabaté M., Ferreiro J.L., et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 2010, 55:1139-1146.